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Major depressive disorder (MDD) remains a huge personal and societal encumbrance.
Particularly burdensome is a virulent subtype of MDD, treatment resistant major depression (TMRD), which afflicts 15–30% of MDD patients. There has been recent interest in
N-methyl-d-aspartate receptors (NMDARs) as targets for treatment of MDD and perhaps
TMRD. To date, most pre-clinical and clinical studies have focused on ketamine, although
psychotomimetic and other side effects may limit ketamine’s utility. These considerations
prompted a recent promising pilot clinical trial of nitrous oxide, an NMDAR antagonist
that acts through a mechanism distinct from that of ketamine, in patients with severe
TRMD. In this paper, we review the clinical picture of TRMD as a subtype of MDD, the
evolution of ketamine as a fast-acting antidepressant, and clinical and basic science
studies supporting the possible use of nitrous oxide as a rapid antidepressant.
Keywords: ketamine, suicide, hippocampus, metaplasticity, NMDA receptors, antidepressant

INTRODUCTION
Major depressive disorder (MDD) is a common and costly psychiatric illness resulting in substantial
suffering and death (1–4). While current treatments for MDD are effective, they are typically slow
to work requiring weeks of administration before significant benefits are observed, and are associated with side effects that limit efficacy and patient tolerance (5). Compounding these problems,
Abbreviations: AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; BDI, Beck depression inventory;
BDNF, brain-derived neurotrophic factor; BP, bipolar disorder; CNS, central nervous system; CRPS, chronic regional pain
syndrome; CBT, cognitive-behavioral therapy; DSM-V, Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition;
EMA, ecological momentary assessments; ECT, electroconvulsive therapy; EEG, electroencephalogram; fMRI, functional
magnetic resonance imaging; GABA, γ-aminobutyric acid; EC50, half-maximal effective concentration; HDRS, Hamilton
Depression Rating Scale; HVA, high voltage-activated calcium currents; IPT, interpersonal therapy; LTD, long-term depression;
LTP, long-term potentiation; LVA, low voltage activated calcium currents; MADRS, Montgomery–Asberg Depression Rating
Scale; MAOIs, monoamine oxidase inhibitors; MCO, metal catalyzed oxidation; MDD, major depressive disorder; mTOR,
mammalian target of rapamycin; NO, nitric oxide; NMDARs, N-methyl-d-aspartate receptors; PCP, phencyclidine; PTSD,
post-traumatic stress disorder; ROS, reactive oxygen species; rTMS, repetitive transcranial magnetic stimulation; SSRIs, selective serotonin reuptake inhibitors; SNRIs, serotonin and norepinephrine uptake inhibitors; TCAs, tricyclic antidepressants;
TRMD, treatment-resistant major depression; VAS, visual analog scales; VNS, vagus nerve stimulation.
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about 15–30% of patients with MDD fail to respond to available
treatments (6). These latter features have prompted the need to
identify faster and more efficacious antidepressant strategies.
Dating to studies initiated in the late 1990s (7), there is increasing evidence that the dissociative anesthetic, ketamine, has rapid
antidepressant efficacy in subjects with MDD, including those
with treatment-resistant major depression (TRMD). Ketamine
differs from currently available antidepressant medications
in being a non-competitive, use-dependent inhibitor of the
N-methyl-d-aspartate class of glutamate receptors (NMDARs),
and thus brings a potentially novel mechanism into play in
developing new MDD treatments (8). Ketamine, however, is also
a psychotomimetic, and in fact has been studied as such (9). This
has prompted efforts to identify other NMDAR antagonists that
have fewer side effects and more prolonged antidepressant effects
compared to ketamine. Work from our labs years ago identified
nitrous oxide as an NMDAR antagonist with mechanisms distinct
from those of ketamine (10). Nagele et al. (11) recently conducted
a pilot, proof-of-concept study using nitrous oxide (“laughing
gas”) inhalation, as a potential treatment for TRMD. Although
tempting to speculate that clinical benefit arises from NMDAR
antagonism, nitrous oxide has other potential cellular targets that
should be considered. In this paper, we will review the concepts
of MDD and TRMD, the use of ketamine for TRMD, and work
describing the actions and potential mechanisms of nitrous oxide
as a rapidly acting antidepressant. The review is aimed at neuroscientists and those working in mental health fields.

various symptoms is to view them in terms of brain networks that
are dysfunctional in major psychiatric illnesses, the networks that
underlie emotional processing, motivation, and cognition (13).
In this context, the low mood of depression likely reflects changes
in the circuitry underlying emotional regulation (the ability to
attach meaning to things and people). Certain other symptoms
reflect abnormalities in cognition including the ability to focus
attention and to hold items in working memory for processing
(reflected in poor concentration and memory difficulties). MDD
is also associated with significant changes in the brain’s motivation/reward system, the circuitry that allows humans to set goals
and work toward those goals. One can interpret the problems
with loss of interest in pleasurable activities, changes in appetite
and energy levels, altered movements, and even suicidal ideation
in this context (Figure 1).
It is important to emphasize that MDD is unlikely a single
illness (13). Rather multiple illnesses of differing etiologies can
produce this collection of symptoms. Furthermore, even within
a given etiology, some individuals will have almost completely
different symptoms, given that only five of nine symptoms are
required for the MDD diagnosis. Furthermore, multiple subtypes
of depression can be described depending on co-morbid conditions. Some patients with MDD have a heavy familial diathesis for
MDD but do not meet diagnostic criteria for any other psychiatric disorder. In an older nomenclature, these individuals were
described as having “primary” depression (sometimes called
familial pure depression), meaning that MDD was the first, and in
many cases, the only psychiatric disorder present (14). Similarly,
individuals with bipolar disorder (BP) who experience episodes
of both mania and MDD exhibit depressive symptoms that are
often identical to persons who only have depression. Yet, the
courses of their illness and their responses to treatments, while
overlapping, have important differences. Further complicating
the MDD diagnosis, individuals with psychosis (delusions and/
or hallucinations) in the context of MDD require treatments that
differ from MDD uncomplicated by psychotic symptoms. Similar
considerations can be given for MDD arising in the context

MAJOR DEPRESSIVE DISORDER
Major depressive disorder is among the leading causes of disability, with disability defined as an inability to work productively or
to live independently (3). Furthermore, MDD is a leading cause
of suicide, and the presence of depression adds to the burden and
adverse outcomes of primary medical illnesses, including heart
disease, diabetes and cancer, among others (4). Current treatments
for MDD include multiple classes of medications, a variety of
neuromodulation treatments including electroconvulsive therapy
(ECT), repetitive transcranial magnetic stimulation (rTMS), and
vagus nerve stimulation (VNS), as well as evidence-based forms
of psychotherapy such as cognitive-behavioral therapy (CBT) and
interpersonal therapy (IPT).
As currently defined, MDD is a syndrome, meaning a collection
of symptoms of undefined etiology that occur together over time.
In the American Psychiatric Associations’ current Diagnostic and
Statistical Manual of Mental Disorders-Fifth Edition (DSM-V)
(12), a major depressive episode is characterized by a subset of
nine clinical symptoms. These symptoms include: (1) low (sad)
mood, (2) loss of interest in usual, particularly pleasurable activities, (3) change in appetite and body weight, (4) sleep disturbance,
(5) dampened energy levels (fatigue), (6) increased (agitation) or
decreased (retardation) motor activity, (7) feelings of excessive guilt
and/or worthlessness, (8) diminished ability to focus attention and
concentrate, and (9) recurrent thoughts of death and suicide.
The various symptoms of MDD can be difficult to conceptualize,
but include symptoms that are associated with reactions to severe
and persistent stressors. An alternative way to characterize the
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FIGURE 1 | The scheme lists symptoms of depression according to
changes in brain networks underlying emotion, motivation and
cognition. Sleep disturbances may reflect homeostatic corrective efforts.
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(and subsequent to the onset) of other psychiatric disorders,
including substance use disorders, personality disorders, anxiety
disorders, obsessive–compulsive disorder, and post-traumatic
stress disorder (PTSD). Similarly, MDD occurring in the presence of major medical illnesses can have a more complicated
course in which the presence of MDD and the medical illnesses
bi-directionally worsens outcomes (4). The complexities noted
above also raise the likelihood that there can be vastly different
responses to treatment across the spectrum of MDD, and large
scale clinical effectiveness trials highlight this complexity (15).

these efforts describe TRMD on an increasing scale of severity
based on the number of “adequate” trials of antidepressant treatment that have been failed, with “adequate” being defined by
dose and duration of the trial. In a system devised by Thase and
Rush (22), TRMD is rated on a 5-point scale with the most severe
degree of refractoriness involving failure of multiple medications
and a course of bilateral ECT. Fava (23) described a method
for staging TRMD based on rating the adequacy of dosing and
duration of treatment, use of augmentation strategies (e.g.,
lithium, anticonvulsants, stimulants, and buspirone), and ECT.
The more recent Maudsley Staging Method for TRMD provides
a multidimensional system based on clinical and treatment factors (24). The latter method involves documenting the number
of treatment failures including ECT and augmentation strategies
while taking into account symptom severity and illness duration.
In an effort to deal with the common problem of TRMD
and its complexity, Conway and colleagues (25) established the
Washington University TRMD Clinic. The goal of this clinic is to
provide a systematic and comprehensive evaluation and consultation program for persons with well defined TRMD, focusing primarily on patients with pure unipolar MDD. Individuals accepted
into this clinic report histories of multiple, well-documented
antidepressant treatment failures, but the program excludes
patients with BPs, personality disorders, schizophrenia and/or
schizoaffective disorder, active psychosis, or active substance use
disorder (except nicotine use). Individuals in the TRMD clinic
must also consent for release of all medical records so that diagnoses and treatments can be adequately characterized by chart
review plus clinical diagnostic interview.
Observations on the first 79 patients evaluated in the TRMD
Clinic have been reported elsewhere (25) but are instructive and
relevant to the pilot clinical study of nitrous oxide described
below. Patients seen in the TRMD Clinic range in age from 19
to 85 years and have an early onset of MDD, averaging 24.3 years
of age at onset. This is consistent with previous studies also suggesting that TRMD has a considerably earlier mean age of onset
than non-TRMD depression (17, 20, 26, 27). The TRMD clinic
patients were also found to have a high rate of mood disorder
in first degree relatives: (62% having a first degree relative with
MDD vs. 5.1–17.5% in the general MDD population (28), and
14% having a first degree relative with BP).
Younger age of MDD onset was associated with family history
(first or second degree relative) of mood disorder (r = −0.26,
p = 0.024; Figure 2) (27). Similarly, there was a statistically
significant earlier mean age of MDD onset in those TRMD
patients reporting a first or second degree relative with BP
(mean = 18.3 years, SD = 6.7, N = 16) compared to those reporting no bipolar relatives (mean = 25.7 years, SD = 14.7, N = 62;
t = 2.9, p = 0.005). This relationship supports the hypothesis that
a subset of TRMD patients may represent a variant of BP. This is a
potentially critical observation, as it may suggest the need for different clinical therapeutic approaches in these patients (29–33).
The TRMD clinic patients have spent almost half their lives
in a depressed state: (mean of about 20 years depressed; range
5–50 years). Recurrent episodes are the norm, although 30%
report one continuous episode of MDD. Based on MADRS
scores, 90% of patients exhibit moderate to severe symptoms at

TREATMENT-RESISTANT MAJOR
DEPRESSION
Given the heterogeneity of MDD, it is not surprising that the
course of MDD can be highly variable, ranging from single
episodes in some people to recurring and frequent episodes in
others, and chronic unremitting symptoms in yet others. For
most individuals, repeated episodes of illness are the norm with
periods of illness typically ranging from several months to a
year or longer. About 80% of persons with MDD have at least
one recurrence during a lifetime, usually within 5 years of their
initial episode (16), and individuals with an increased number of
lifetime episodes require longer durations of treatment, in some
cases, for life (17, 18). While current antidepressant treatments
are effective, between 15 and 30% of individuals with pure MDD
fail multiple treatments (1, 19–21).
Despite being relatively common in psychiatric practice,
TRMD is not well defined across studies. In classifying individuals with MDD as being treatment resistant, it is important that
refractoriness reflects treatment failure and not intolerance of
side effects, treatment non-compliance, or inadequate dose/duration of treatment. Compounding this challenge is a problem with
defining the degree of response to treatment. In clinical trials,
treatment “response” is often defined as a 50% improvement in
symptoms, whereas “remission” refers to having few or no residual
symptoms following treatment using standardized instruments
to rate symptoms including the Hamilton Depression Rating
Scale (HDRS), the Montgomery–Asberg Depression Rating Scale
(MADRS), and the Beck Depression Inventory (BDI), among
others. Repeated studies demonstrate that remission is the goal
of treatment; achieving remission gives the best chance to avoid
MDD recurrence. Furthermore, “response” to treatment (50%
improvement) can still reflect a state of significant dysfunction.
MDD patients with multiple residual symptoms show increasing
refractoriness to subsequent antidepressants trials (15).
Given the prevalence of MDD and TRMD, it is clear that
TRMD is common, perhaps affecting as many as 3.5 million
persons in the United States alone (1, 21). This ranks TRMD
as more common than many disabling neurological conditions
including epilepsy and multiple sclerosis (2). The early onset of
TRMD, high medical utilization and disability also make TRMD
very costly in terms of suffering, health care expenditures, and
years of lost productivity.
There have been several attempts to characterize degrees of
TRMD using clinical and treatment response criteria. In general,
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FIGURE 2 | The graph shows the age of onset of MDD in the 79 patients evaluated in the TRMD clinic. The bars show the mean age of onset of MDD in
these subjects according to family history including family members with MDD and bipolar disorder (BP). This figure has been adapted and modified from data
presented in Ref. (25).

the time of first evaluation. As supported in the literature, treatment resistance is a significant risk factor for suicide attempts:
25% have attempted suicide at some point in their life with an
average of 3.4 suicide attempts per individual with an attempt
(34, 35). Almost two-thirds (63%) of these patients have been
hospitalized for depression and 33% are on disability. Similar to
non-TRMD MDD, women outnumbered men by 2–1, consistent
with other TRMD studies (16, 17, 23, 26, 27).
Treatment-resistant major depression patients evaluated at
the Washington University TRMD Clinic could be considered
“hyper-resistant”: on average, these patients have failed 8 “adequate” treatment trials at the time of index evaluation (Figure 3).
The most common treatment trials were with SSRIs (99% of
patients): on average patients have received 3.6 trials of an SSRI,
either alone or in combination with other treatments. SNRIs had
been tried in 95% of subjects, bupropion in 89%, and evidencedbased forms of psychotherapy in 93%. Augmentation trials in
which specific medications are added to ongoing treatment with
a standard antidepressant were common with 86% receiving
an antipsychotic (typically aripiprazole, or quetiapine), lithium
(58%), stimulants (54%), thyroid supplementation (34%), and/or
buspirone (23%). Interestingly, first-generation antidepressants
were less commonly used with only 57% having received a TCA
and 37% a MAOI. Surprisingly, the most aggressive and arguably
most effective treatment for TRMD, ECT, was only attempted in
60% of these highly refractory individuals.

studies initiated in the 1990s, there is increasing evidence that
the dissociative anesthetic, ketamine, has rapid antidepressant
effects in subjects with MDD and TRMD. Importantly, the
antidepressant effects of ketamine are observed with a single
intravenous administration of a subanesthetic dose, with most
studies using 0.5 mg/kg infused over 40 min. In the initial pilot
report, Berman et al. (7) described seven subjects with MDD who
showed significant improvement in depressive symptoms within
72 h following ketamine administration. Zarate and colleagues
(36) pursued this finding and reported significant benefits in 18
subjects with TRMD. These individuals showed improvement
in depression ratings 2 h following ketamine infusion. By 24 h
after ketamine about 70% showed a response (50% reduction in
depression scores), and about 30% were in remission (having few
or no symptoms). Thirty-five percent of subjects maintained the
benefits 1 week after ketamine. Ketamine was fairly well tolerated
although there were transient increases in psychotic symptoms
during drug infusion.
The dose of ketamine used in these studies and in most studies
to date is the same as originally used by Krystal and colleagues
(9) in the early 1990s. In the initial studies, 19 healthy volunteers
received a 40 min infusion of ketamine at a dose of 0.5 mg/kg.
The purpose of these studies was to determine whether ketamine
mimicked the symptoms of schizophrenia as a model to study
factors involved in psychosis. The subjects experienced transient changes in perception (sensory illusions), altered thought
content (persecutory ideas), amotivation (a disconnected state),
and cognitive impairment (diminished attention, problems with
word fluency and diminished ability to learn new information).
Thus, the same dose of ketamine now being used routinely in
studies of TRMD is clearly associated with psychotomimetic
and cognitive effects, prompting concerns about the safety and

KETAMINE, NMDARs, AND RAPIDLY
ACTING ANTIDEPRESSANTS
The severe features of TRMD outlined above make it mandatory to find new and more effective treatments. Dating to
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FIGURE 3 | The graph shows the number of antidepressant trials documented in 79 patients evaluated in the TRMD clinic. Based on chart review and
clinical interview, all trials listed in this graph had adequate dose and duration of antidepressant treatment.

tolerability of ketamine in individuals with psychiatric illnesses.
Fortunately, in studies to date the psychotomimetic and cognitive symptoms have been transient, although ketamine also has
effects on heart rate and blood pressure that may limit its use
in certain patient populations. Administration of ketamine in
these studies and subsequent studies was not accompanied by
agents, such as GABA-enhancing agents or antimuscarinics (37),
to prevent psychotomimetic side effects. It is unknown whether
the use of “safening” agents would alter the antidepressant effects
of ketamine.
Since the original human studies of the 1990s, work on ketamine has progressed with emphasis on defining patient groups
and symptoms particularly responsive to the drug. A recent metaanalysis of seven clinical trials involving 147 patients supports the
hypothesis that ketamine has rapid but transient antidepressant
effects after a single administration, with odds ratios for antidepressant response and remission of 9.87 and 14.47, respectively,
24 h following treatment and effects fading over 1–2 weeks (38).
A recent Cochrane review, however, was more restrained and
raised cautionary notes about small sample sizes and risk of bias
(39). Efforts to prolong the antidepressant effects of ketamine
have included repeated infusions, following approaches used for
ECT (40). For example, Murrough and colleagues (41) studied
24 subjects with TRMD treated with six intravenous ketamine
infusions administered three times per week over 12 days. This
group of TRMD patients showed a 71% acute response rate, with
initial effects manifest within 4 h of infusion. The repeated exposures had some beneficial effect, but the median time to relapse
was 18 days even with six treatments. An alternative approach
to prolong the effects comes from the analgesia literature where
longer ketamine infusions are used to treat chronic regional pain
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syndrome (CRPS). Ketamine infusions to treat CRPS have ranged
from several hours to several days. For example, Dahan et al. (42)
infused ketamine at a dose of 5–20 mg/h for 100 h. This prolonged
treatment led to a 67% response rate (vs. 21% for placebo) and
effects lasted about 50 days. Whether such an approach would
be tolerated or effective in TRMD is unknown, but even longer
ketamine infusions have been used elsewhere in chronic pain
(43). Other efforts to prolong ketamine’s effects include intranasal
administration (44).
Beyond TRMD, some evidence suggests that ketamine is
effective in patients with refractory bipolar depression (45) and
chronic post-traumatic stress disorder (PTSD) (46). Other studies indicate that ketamine may have beneficial effects on specific
subsets of depressive symptoms including suicidal ideation (47,
48). An interesting twist is that family history may predict ketamine response. At least two studies indicate that having a positive
family history of alcohol abuse/alcoholism predicts antidepressant response to ketamine (45, 49). Furthermore, prior studies
indicate that recovered alcoholics and persons with high familial
risk for alcoholism have altered responses to ketamine compared
to naïve controls, with dampened psychotomimetic and dissociative symptoms (50–52).

KETAMINE MECHANISMS
Why ketamine? The seminal studies of Krystal and colleagues
(9) were designed to test the hypothesis that hypofunction of
NMDARs is involved in the pathophysiology of schizophrenia
and other psychotic disorders (37, 53). In parallel, Trullas and
Skolnick (54) proposed that NMDAR antagonists might have
antidepressant effects based on studies in animals. NMDARs are

5

December 2015 | Volume 6 | Article 172

Zorumski et al.

Nitrous Oxide and Depression

a class of glutamate-gated cationic channels in which the binding of glutamate promotes the opening of transmembrane ion
channels that allow the influx and efflux of positively charged
ions including Na+, K+, and Ca2+ (55). NMDARs are multimeric
proteins with four subunits. The major NMDARs in mammalian
brain express one of eight GluN1 splice variants along with one or
more GluN2 subunits, or sometimes a GluN3 (GluN3A, GluN3B)
subunit. GluN2 subunits (GluN2A-D) bind agonists (glutamate)
in their extracellular domains, while GluN1 subunits, obligatory
for a functional channel, regulate ion channel function by binding the co-agonists glycine or d-serine. Together the binding of
glutamate and a co-agonist is required for opening (gating) of
NMDAR ion channels (55, 56). Adding to the complexity, multiple other endogenous ions and modulators also bind NMDARs
to regulate ion channel function. These include ionic modulators,
Mg2+, Zn2+, and H+, as well as polyamines, neurosteroids, and
oxysterols (55–57). Mg2+ plays a key role in determining the
properties of NMDARs, producing a form of voltage-dependent
open channel block at membrane potentials near the neuronal
resting membrane potential. When the membrane depolarizes,
Mg2+ exits the NMDAR channel and this allows other cations to
flow in and out of the cell. In effect, NMDARs pass very small
currents at resting membrane potential, but open effectively when
neurons are excited (depolarized). This voltage-dependence contributes strongly to the proposed role of NMDARs as “coincidence
detectors” because their activation requires both presynaptic
(glutamate release) and postsynaptic activation (depolarization)
(55, 56). When both conditions occur, NMDARs participate in
excitatory synaptic function. In turn, activated NMDAR channels are highly permeable to Ca2+, and the influx of Ca2+ activates
second messenger systems and promotes Hebbian synaptic
plasticity, including long-term potentiation (LTP) and long-term
depression (LTD), forms of lasting synaptic change thought to
underlie learning and memory (58).
In the 1980s, a series of studies dating to David Lodge and
colleagues (59) found that ketamine, its structural analog, phencyclidine (PCP), and the experimental agent, MK-801, are noncompetitive/uncompetitive NMDAR antagonists. These agents
inhibit responses mediated by NMDARs, but do not alter the
binding of agonists to NMDARs unlike competitive antagonists
(60). Biophysical experiments showed that ketamine and its analogs have unique mechanisms. These agents do not act on closed
NMDARs. Rather, the ability of ketamine to block responses
requires that NMDAR ion channels open (61, 62). When the ion
channels are open, ketamine enters the channel and binds a site
that is electrically deep within the channel pore to occlude the
flow of ions. In contrast, memantine, another NMDAR channel
blocker also binds a superficial site within the channel, perhaps
accounting for differences from ketamine (63). When ketamine
binds the deep site, the ion channel is able to close around the
blocking molecule creating a longer-lived ion channel block. This
is referred to as “trapping ion channel block” (61, 63). Relief of
this block requires that glutamate (or other agonist) binds the
receptor to promote channel opening. Depolarization of the
neuronal membrane speeds blocker dissociation. As mentioned,
ketamine shares these properties with PCP and MK-801, but is
less potent than the other two agents, resulting mainly from faster
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dissociation from the open channel. While block of NMDARs is
not the only effect of ketamine, and effects on other receptors and
channels likely contribute to some pharmacological actions, the
effects of ketamine on NMDARs appear to play critical roles in
the ability of this agent to produce anesthetic, psychotomimetic,
analgesic and possibly antidepressant effects. NMDARs are also
likely to underlie the abuse potential of ketamine.
How ketamine produces its beneficial effects at cellular and
molecular levels is an area of active investigation. Importantly, the
effective antidepressant doses of ketamine are subanesthetic and
at these concentrations, ketamine only partially inhibits NMDAR
currents with responses mediated by AMPA-type glutamate
receptors and unblocked NMDARs remaining intact (likely <50%
NMDAR block in the presence of physiological Mg2+) (64–67).
Studies in animals and in vitro indicate that ketamine has disinhibitory effects in neocortex that may result from preferential
dampening of excitation of GABAergic interneurons resulting in
stimulation of pyramidal (excitatory) neurons (68). Preferential
inhibition of NMDARs in select cell types might be achieved
through the complex dependence of ketamine block on agonist
presentation, third-party endogenous modulators (e.g., positive
allosteric modulators, Mg2+), and activity levels (64, 69, 70).
Because ketamine’s antidepressant effects greatly outlive
psychotomimetic effects and systemic drug presence, it is likely
that ketamine triggers persistent biochemical, synaptic and/
or morphological changes. Consistent with this idea, ketamine
indirectly enhances AMPAR-mediated excitatory synaptic function in frontal cortex (71) and hippocampus (72), resulting in
persistent increases in synaptic efficacy and changes in neuronal
structure. Other key targets for ketamine’s antidepressant effects
in rodents appear to include infralimbic prefrontal cortex (73).
Mechanisms contributing to synaptic enhancement may differ between regions. In frontal cortex, synaptic enhancement
involves activation of the mammalian target of rapamycin
(mTOR) kinase and effectors downstream of mTOR (71, 74, 75),
while in hippocampus effects on eukaryotic elongation factor
2 kinase contribute (72). Other key components of ketamineinduced signaling appear to include brain-derived neurotrophic
factor (BDNF) and perhaps glycogen synthase kinase 3β (72,
74). Effects of ketamine in rodent hippocampus may specifically
involve effects on spontaneous synaptic transmission (72, 76).
Some evidence suggests that effects of ketamine on a specific
subtype of NMDARs expressing GluN2B subunits may be particularly important in synaptic and behavioral effects in animals
(77), and that activation of non-GluN2B expressing NMDARs
that are not blocked by ketamine may drive some of the synaptic
and metaplastic effects of ketamine on hippocampal network
function (78). The latter findings are also consistent with data
indicating that a selective inhibitor of GluN1/GluN2B NMDARs
has antidepressant efficacy in humans (79). Other work indicates
that selective blockade of NMDARs expressing either GluN2A or
GluN2B has antidepressant-like effects whereas concurrent block
of both subtypes results in stereotyped and possibly psychotic-like
behaviors (80). It is interesting to note that these subunit selective
blockers act through different pharmacological mechanisms than
ketamine; they are not channel blockers. Data also indicate that
activation of AMPARs, the primary mediators of fast glutamatergic
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transmission are important in the effects of ketamine (71, 72), but
it is unclear whether this involves specific downstream effects of
AMPARs or the fact that depolarization mediated by AMPARs is
important for activation of unblocked NMDARs.

antidepressants are not channel blockers, not all NMDAR channel blockers have significant antidepressant effects. For example,
memantine, an agent used to slow progression in Alzheimer’s
disease, is a non-competitive NMDAR antagonist and channel
blocker with limited antidepressant efficacy (17, 91). The lack of
antidepressant efficacy may result from pharmacokinetic differences and/or selective effects of memantine on NMDAR channels
and subtypes (92, 93). On the other hand, differences between
memantine and ketamine on NMDAR currents have been difficult to demonstrate in spontaneously active neuronal networks
(70) unless third-party positive modulators of NMDARs are
present (71). Thus, key pharmacological features predicting antidepressant effects are murky at the moment, and an empirical,
trial-and-error approach appears warranted.

KETAMINE AND BRAIN CIRCUITS
Several studies have begun to address how ketamine affects
human brain circuitry involved in cognition, motivation, and
emotion. Some evidence using functional magnetic resonance
imaging (fMRI) suggests that depression reflects a state of
functional resting state hyperconnectivity among several brain
networks including the default mode network that processes
internal (self) information and networks underlying cognitive
control and affective processing. Increased connectivity in these
networks appears to involve increased activity in regions of
dorsal medial prefrontal cortex referred to as the “dorsal nexus”
and improvement in depressive symptoms is associated with
dampened dorsal nexus activity (81). Scheidegger and colleagues
(82) found that within 24 h after infusion of ketamine in normal
subjects, there was diminished resting state connectivity of the
default mode, cognitive control, and affective networks with the
dorsal nexus, suggesting a plausible brain circuitry mechanism
for antidepressant actions. Other work indicates that ketamine
acutely dampens both the activation and deactivation of brain
regions involved in a working memory task, although these latter
findings may be more relevant to changes associated with schizophrenia and ketamine-induced psychotic symptoms (83, 84).
Ketamine also produces acute glutamate-mediated hippocampal
hypermetabolism, and this may contribute to interneuron dysfunction and acute psychotic symptoms (85).
Recent work using magnetoencephalography to map changes
in regional brain interactions found that subanesthetic ketamine
decreases the apparent gain of pyramidal neurons in parietal cortex, with diminished glutamate-mediated connectivity between
frontal and parietal regions (86). Changes in the signal-to-noise
ratio of information processing in lateral prefrontal neurons have
also been observed during working memory tasks in macaques
following subanesthetic ketamine (87). Taken together with
studies in rodents, it appears that ketamine may enhance excitatory synaptic function in some brain regions (e.g., hippocampus
and frontal cortex) while dampening excitatory connectivity in
regions that are overactive in MDD (e.g., default mode, affective
and cognitive control networks, and dorsal nexus).

NITROUS OXIDE AS A RAPIDLY ACTING
ANTIDEPRESSANT
Nitrous oxide is an inhalational anesthetic with analgesic and
anxiolytic actions that has been in clinical use for more than
150 years (94). Acute euphorogenic effects of nitrous oxide (hence
the name “laughing gas”) have also led to recreational use and
abuse, and speculation that it might have antidepressant properties (95). In the late 1990s, nitrous oxide was found to be a noncompetitive NMDAR inhibitor, acting by a mechanism distinct
from ketamine and not involving open channel block (10, 96).
Based on these early findings and evolving results from antidepressant studies of ketamine, Nagele and colleagues (11) pursued
a pilot, proof of concept clinical trial using a subanesthetic dose of
nitrous oxide in a group of 20 patients with TRMD. The dose used
for this study was 50% nitrous oxide with 50% oxygen inhaled
for 1 h in a single session. This dose was selected based on its
routine use for analgesia and mild sedation in anesthesiology and
dentistry. The effects of nitrous were compared to a placebo gas
mixture (50% nitrogen − 50% oxygen × 1 h) in a double-blind,
cross-over design with nitrous oxide and placebo administered
1 week apart. Patients were required to have failed at least two
adequate trials of antidepressant treatments in the current episode
of MDD while having a baseline depression score on the HDRS
above 18. The trial excluded patients with BP, psychosis, panic disorder, obsessive–compulsive disorder, personality disorders, and
active substance use disorder within the past 12 months except for
nicotine. Also excluded were individuals with acute medical illnesses, acute suicidal behavior and prior treatment with ketamine
or ongoing ECT. Patients were required to remain on their routine
antidepressant treatments for 4 weeks prior to and during the trial.
Patients enrolled in this study averaged 48 years of age, were
60% women, and had experienced a mean lifetime history of
19 years of MDD and eight documented antidepressant failures; four had failed ECT and three had failed VNS; thus, the
patients studied with nitrous oxide mirrored the patients in
the TRMD Clinic and involved individuals with a high degree
of treatment refractoriness (25). Interestingly, 10 patients had a
history of migraine headaches and 4 had a history of corrected
hypothyroidism. Significant improvement in depression ratings
in this highly treatment-resistant cohort were observed at 24 h

OTHER NMDAR ANTAGONISTS: NOT ALL
ARE ANTIDEPRESSANT
The clinical results with ketamine in TRMD have prompted a
search for other NMDAR antagonists that share ketamine’s rapid
antidepressant actions while having fewer side effects (88). These
include agents with more selective actions at NMDAR subtypes,
including selective GluN1/GluN2B NMDAR antagonists (79) as
well as NMDAR antagonists that modulate glycine/d-serine sites
on NMDARs, and others that have different effects on NMDAR
channels (88–90). Although some candidate NMDAR antagonist
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after nitrous oxide administration with a median reduction of
5.5 points on HDRS (95% CI −2.5 to −8.5 points), the primary
endpoint for the study. Four patients were rated as showing a
response to treatment (50% decrease in HDRS) and one of these
individuals showed remission of MDD symptoms (HDRS < 7)
compared to one patient with response to placebo and no
placebo-treated patients with remission. MDD symptoms that
were particularly sensitive to nitrous oxide included depressed
mood, suicidal ideation, guilt, and psychological symptoms of
anxiety. A significant subset of those patients experiencing an
antidepressant response to nitrous inhalation maintained their
response at 1 week. This latter feature confounded the cross-over
study design because benefits were still observed at the time of the
subsequent treatment. Nitrous oxide was well tolerated and side
effects were short-lived following termination of nitrous administration. Side-effects included nausea and vomiting, headache and
increased anxiety/panic, and necessitated shortening the duration of nitrous administration in 5 of the 20 patients (vs. none of
the placebo administrations).

To date, few studies have examined how nitrous oxide alters
neuronal network activity. In the CA1 region of rat hippocampal
slices, acute nitrous perfusion resulted in disinhibition of population spike firing without significant effects on AMPAR-mediated
synaptic potentials (97). The disinhibition was occluded by picrotoxin, a GABA-A receptor antagonist, suggesting that nitrous
oxide altered local synaptic inhibition in the CA1 region. In these
studies, the lack of effect of nitrous oxide on excitatory synaptic
potentials in the CA1 Schaffer collateral pathways suggests that
its actions may differ from ketamine (72). However, the nitrous
oxide studies were done in hippocampal slices from juvenile
rats and ketamine’s ability to enhance CA1 synaptic responses
appears to be age-dependent and most prominent in slices from
adult rodents (98). Nonetheless, the disinhibitory effects on CA1
function observed in young rodents is consistent with apparent
changes in population spike firing observed with ketamine at the
same age (78) and studies of ketamine in cortex (68).
There is limited information about the effects of nitrous oxide
on human brain networks. Studies using quantitative electroencephalographic (EEG) recordings indicate that nitrous oxide
dampens functional connectivity in superficial parietal networks
with more widespread changes in frontal activity (99). Other
work has found that nitrous oxide (at 20–40%) acutely decreases
frontal slow wave (delta) activity, but this is followed by enhanced
theta activity after drug washout (100). These EEG effects of
nitrous differ from other general anesthetics. Studies examining
the effects of nitrous on connectivity of brain networks underlying depression are lacking.
Few studies have directly linked nitrous oxide’s effects on
NMDARs to specific behaviors. In the roundworm, Caenorhabditis
elegans, Nagele and colleagues (101) found that nitrous oxide
alters motor reversal behavior. These effects of nitrous were
not observed in animals lacking functional NMDARs, but were
present in worms with altered expression of non-NMDARs.
Furthermore, nitrous oxide inhibited motor reversal behavior
upon re-expression of NMDARs in the NMDAR mutant worms.
At 70%, nitrous oxide had no effect on chemotaxis, feeding,
defecation or rate of locomotion. Some evidence in mice with
targeted deletion of the GluN1 NMDAR subunit indicates that
NMDARs are involved in the sedating effects of nitrous oxide
(102), although this finding has not been replicated in other
studies and secondary effects on monoaminergic activity may
be important for immobility in GluN1 knockout animals (103).
Other work suggests that discriminative stimulus effects of
nitrous oxide at least partially involve NMDARs (104).

NITROUS OXIDE AND NMDARs
How does nitrous oxide produce its effects? Studies in the
late 1990s provided the first evidence that nitrous oxide is a
non-competitive NMDAR antagonist. In these studies, nitrous
blocked NMDAR-activated currents in cultured hippocampal
neurons with an approximate half-maximal effective concentration (EC50) of 30–40% (95). Even at 80%, however, nitrous was
only a partial inhibitor of NMDAR responses producing less than
70% block. Unlike ketamine, nitrous oxides effects were weakly
voltage-dependent and did not display the kinetic effects on
NMDAR currents expected of an open channel blocker, including having no effect on the decay of NMDAR-mediated synaptic
currents (10). Nitrous oxide had minimal effects on GABA-A
receptors, with very weak (~20%) potentiation observed at
80% nitrous. Weak effects were also observed on AMPA/kainate type glutamate receptors (non-NMDARs) with about 30%
block of kainate currents (mediated mainly by AMPARs in this
preparation) at 80% nitrous. Effects on AMPAR currents were
not voltage dependent. Nitrous had small inhibitory effects on
synaptic currents mediated by AMPARs but did not alter pairedpulse plasticity of these responses. This latter effect is important
because it indicates that nitrous oxide is unlikely to have large
presynaptic effects on glutamate transmission. Consistent with
this, nitrous oxide failed to inhibit high voltage activated (HVA)
calcium currents; HVA currents provide the calcium signal that
triggers synaptic glutamate release.
The effects of nitrous oxide as an NMDAR antagonist in
hippocampal neurons were consistent with histological changes
observed in the cortex of rodents in vivo. Prior studies showed that
NMDAR antagonists, including ketamine, produce vacuoles in
neurons in the posterior cingulate cortex following systemic administration (37). Nitrous oxide mimicked these effects (96). Similarly,
NMDAR antagonists block glutamate-mediated excitotoxicity and
nitrous oxide mimicked these effects as well. Thus, physiological
and histological studies indicate that nitrous oxide has NMDAR
antagonistic, neuroprotective, and neurotoxic actions.
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VOLTAGE-ACTIVATED CALCIUM
CHANNELS
The analgesic effects of nitrous oxide have prompted studies
examining whether the drug alters ion channels or signaling systems involved in pain processing other than NMDARs. Todorovic
and colleagues (105) found that nitrous oxide is a weak inhibitor
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and activation of α-adrenoceptors in brainstem and spinal cord
contribute to antinociceptive effects in rats (116, 117).
It is difficult to compare the potency of nitrous oxide for effects
on various targets across studies because complete concentrationresponse data are not available for many effects. Nonetheless,
nitrous oxide blocks NMDARs by 50% at a concentration of
30%, making this one of its most potent effects (96). Effects on
opiate receptors are also potent with 30% nitrous having analgesic actions equivalent to 10–15 mg morphine (118). Actions at
T-channels (30% block at 80% nitrous) (105) and TREK-1 (30%
activation at 80% nitrous) (110) are weaker.
In addition to analgesia and anesthesia, nitrous oxide is used
clinically for anxiolytic effects. Consistent with this, acute nitrous
oxide shows anxiolytic properties in the elevated plus maze (119),
light-dark exploration (120), social interaction (121), and condition burying tests (122) that are used as animal models of anxiety.
These effects have been observed during 15–30 min exposures to
nitrous oxide at concentrations of 25–75%. How nitrous oxide
produces these effects is not certain, although some evidence suggests a role for serotonin and GABA-A/benzodiazepine receptors
(123) and the release of the endogenous messenger, nitric oxide
(NO) (118, 124). Cyclic GMP, a messenger activated by NO, also
appears to participate in the anti-anxiety effects of nitrous oxide
in rodents (125). NO has presynaptic effects on glutamate release,
and nitrous oxide dampens NMDAR-mediated synaptic responses
in the amygdala by both postsynaptic and presynaptic actions
(126). Zarate and Machado-Vieira (127) postulated that the ability
of nitrous oxide to generate NO may be important in its antidepressant actions. Consistent with this, some synaptic and memory
impairing effects of ketamine involve NO synthesis (78, 128).

of low voltage activated (LVA, T-type) calcium channels, producing about 30% depression of LVA currents at 80% nitrous in rat
sensory neurons. Interestingly, the ability of nitrous to block LVA
currents is selective for the Cav3.2 LVA subtype that is expressed
in sensory neurons, with no effect on Cav3.1. Other studies using
site directed mutagenesis have found that effects on Cav3.2 likely
involve metal catalyzed oxidation (MCO) at histidine 191 (H191)
(106, 107). MCO is a form of the redox modulation that is known
to alter the function of multiple ion channels including LVA channels (108) and NMDARs (109). Consistent with this, Orestes et al.
(106) showed that nitrous oxide generates reactive oxygen species
(ROS) in the presence of iron, and metal chelators (that scavenge
iron) and catalase (a ROS scavenger) attenuate effects of nitrous
on LVA channels. Furthermore, mutant mice with targeted deletion of Cav3.2 show diminished analgesia in response to nitrous
oxide, indicating that this channel is relevant to peripheral analgesic effects of nitrous oxide in vivo. Similarly, EUK-134, an agent
that mimics superoxide dismutase and catalase, also dampens
nitrous oxide-induced analgesia (106). Nitrous oxide does not
inhibit high voltage activated (HVA) calcium currents in sensory
or hippocampal neurons (10, 105).

OTHER POTENTIAL MECHANISMS OF
NITROUS OXIDE
Nitrous oxide has other effects that could contribute to its clinical
and behavioral actions, particularly analgesia (Figure 4). These
include the ability to activate the two pore-domain potassium
channel, TREK-1 (110), as well as to weakly block GABA-C
receptors and serotonin-type 3 receptors (111). Nitrous is also
a partial inhibitor of certain nicotinic acetylcholine receptors,
producing 40% inhibition of α4β2 nicotinic receptors but only
7% inhibition of α4β4 receptors (111). Other evidence indicates
that nitrous oxide has opioid-like effects that could contribute
to analgesia and perhaps to psychotropic effects (112–115).
Nitrous oxide also has effects on brainstem adrenergic neurons

ONGOING ISSUES AND FUTURE
CONSIDERATIONS
Studies examining the acute antidepressant effects of ketamine
and other NMDAR antagonists are a growth area in psychiatry,
providing inroads into what may be truly novel targets and treatments for MDD and TRMD (8, 88). The ability of these agents to
rapidly dampen suicidal ideation leads to the intriguing possibility
of administering ketamine-like drugs in emergency and inpatient
settings while other antidepressant strategies are initiated. Despite
encouraging results there are major challenges with the use of
ketamine, including acute psychotomimetic and cognitiveimpairing actions, along with abuse potential. It is also important
to remain cognizant of the challenges that have plagued attempts
to develop NMDAR antagonists as treatments for neurodegenerative conditions, including neurotoxic effects (37).
The recent pilot findings with nitrous oxide for TRMD are
intriguing and indicate that mechanisms other than channel
block for inhibiting NMDAR function may be effective for treating patients with severe and refractory mood disorders. Like
ketamine, nitrous oxide appears to have rapid beneficial effects
on suicidal ideation. Importantly, while nitrous oxide, like ketamine has abuse potential, it does not appear to share ketamine’s
psychotomimetic or cognitive side effects, making it an attractive
alternative for therapeutic development. Nitrous oxide is known,

FIGURE 4 | The list includes various effects of nitrous oxide that could
contribute to antidepressant and other CNS effects. Supporting studies
are described in the text.
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however, to impair methionine synthesis via inactivating effects
on vitamin B12 (cobalamin), particularly following repeated or
prolonged administrations (94). In the pilot antidepressant trial,
a single 1 h administration of nitrous oxide did not alter vitamin
B12 activity (11).
As is true of any pilot study, there are now many more
questions than answers including questions that are relevant
for ketamine (129). The pilot nitrous oxide study used a single
dose and a single 1-h administration. The dose (50% nitrous
oxide) was based on use in anesthesiology and dentistry, while
the duration (1 h) was selected to mimic ketamine infusions
for TRMD. Despite initial positive results, it is unclear whether
either of these parameters is optimal or whether lower doses
and altered durations of exposure would maintain or improve
benefits while diminishing acute side effects and enhancing
patient tolerability during nitrous inhalation (100). Similar to
ketamine, it is unclear how long the benefits of nitrous oxide
last and how to sustain the benefits. The pilot study was conducted in highly refractory TRMD subjects; whether nitrous
oxide will have a different impact in less refractory patients
requires further study. Similarly, we have no information
about the response of MDD in the context of other psychiatric
disorders including BP, anxiety disorders, personality disorders
and substance use disorders, or whether nitrous oxide will
be effective in acute inpatient settings. While nitrous oxide
is relatively easy to use in outpatient settings such as dental
offices, monitoring cardiovascular and respiratory parameters
as well as recovery from sedation will be important for use in
psychiatry. Potential neurotoxic effects of nitrous oxide (and
ketamine) also must be considered with high doses and more
prolonged administration (96).
Another major issue in studies of rapid antidepressants
concerns how best to measure changes in depression. Current
instruments (e.g., HDRS, MADRS, and BDI) are limited and
query symptoms that are of longer duration and less amenable
to acute change (e.g., sleep disturbances, appetite, and weight
changes). Thus, the validity of these instruments when dealing
with rapid changes requires further evaluation. Efforts using
other instruments, perhaps including visual analog scales and/
or ecological momentary assessments may be more appropriate
going forward.
Similar to other drugs, including ketamine, nitrous oxide is
not specific for NMDARs and alters the function of a number
of other ion channels and proteins involved in neural signaling.
Nonetheless, effects on NMDARs are among the most potent
effects of this agent, making it likely that NMDAR inhibition
contributes, at least in part, to clinical effects, just as it likely
does for ketamine. Although the NMDAR effects of ketamine
may be modulated by regional or temporal differences in agonist
presentation, depolarization state of cells, and by presence of local
endogenous allosteric regulators (63, 69), the effects of nitrous
oxide do not involve ion channel block, particularly the longerlived trapping block associated with ketamine-type agents (10).
Thus, effects of nitrous oxide may be less prone to environmental
conditions. Also, the acute effects of nitrous oxide are faster to
reverse once administration is stopped.

Frontiers in Psychiatry | www.frontiersin.org

Whether nitrous oxide’s effects on NMDARs involve redox
modulation as they do at LVA (T-type) calcium channels (106)
remains to be determined. If this is the case, it opens up the
possibility of developing other agents that target this mechanism, although specificity of effects could be a major problem.
Unlike ketamine, however, nitrous oxide is not metabolized
endogenously to other moieties that are bioactive (67, 130, 131),
and both ketamine and its metabolites affect targets other than
NMDARs that contribute to sedation and CNS effects (132).
Furthermore, in the United States ketamine is sold as a mixture
of S- and R-enantiomers; the S-enantiomer (which is what is used
in Europe) is more potent but the R-enantiomer has biological
activity (133). Thus, despite enthusiasm over the early work on
ketamine and pilot results from nitrous oxide, it is premature to
conclude that effects on NMDARs are the sole mechanism for
antidepressant actions (129).
The clinical trial with nitrous oxide was based on the
evolving literature on ketamine. There are other NMDAR
antagonists used clinically that could also be potentially
developed for therapeutic purposes in psychiatry. Examples
include the gaseous anesthetic, xenon (111, 134), the common
intoxicant, ethanol (alcohol) (135), and the cough suppressant,
dextromethorphan. Whether any of these agents would have
antidepressant efficacy, particularly following acute systemic
administration, is uncertain. Based on the lack of apparent
antidepressant efficacy of memantine (91), however, it seems
unlikely that all NMDAR antagonists will be useful as antidepressants. Nonetheless, understanding why memantine or
these other agents do or do not have significant antidepressant
effects may help clarify key mechanisms underlying psychotropic actions. In fact, preclinical studies with memantine
have already pointed to differences in the ability of this agent
to modulate spontaneous synaptic activity and to enhance synaptic efficacy in the rodent hippocampus relative to ketamine
(93). Differences in pharmacokinetics and route of administration may also be key variables. Other considerations, include
the fact that effective doses of ketamine and nitrous oxide are
subanesthetic (65), indicating that at the effective doses, these
agents only partially inhibit NMDAR currents, resulting in a
significant population of NMDARs that remain unblocked.
Studies in rodents indicate that anesthetic doses of ketamine
that block a higher percentage of NMDARS also block both
antidepressant actions in rodents and synaptic effects in neocortex (71). In hippocampus, complete block of NMDARs
during ketamine administration (or high concentrations
of ketamine alone) prevents synaptic and metaplastic
effects of the drug in the hippocampus (78, 136). Whether
similar effects occur with nitrous oxide and other NMDAR
antagonists is unknown.

SUMMARY
Evolving work on NMDAR antagonists supports their
importance as novel targets for therapeutic development
in neuropsychiatry. Ongoing studies of ketamine and early
results with nitrous oxide are encouraging. While neither of
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these agents is a selective NMDAR antagonist, it is clear that
NMDAR inhibition plays a role in their behavioral effects.
Thus, nitrous oxide is another chapter in the NMDAR depression story and has the potential to open new avenues for rapid
therapeutic effects against severe and refractory forms of
MDD.
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